Pfizer Inc aims to drive profits in coming years with more-responsive and easier-to-manufacture new cancer treatments.
With its French partner Cellectis, Pfizer is in the early stages of developing new cancer treatments called CAR T cells it says has major medical and manufacturing advantages over similar cell therapies being developed by others.
The treatments are T-cells, white blood cells that act as soldiers against foreign invaders, that have been genetically altered to make them better able to spot and attack cancer.
